Right atrial lesions do not improve the efficacy of a complete left atrial lesion set in the surgical treatment of atrial fibrillation, but they do increase procedural morbidity  by Soni, Lori K. et al.
Acquired Cardiovascular Disease Soni et al
A
C
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356Objective: Some have suggested the superiority of biatrial versus left atrial lesions. We sought to analyze our
experience.
Methods: We retrospectively reviewed 305 consecutive patients from 2007 to 2011. Rhythm success was de-
fined as freedom from atrial fibrillation (AF) or flutter determined by 12-lead electrocardiograms at 3-month
intervals. Lesions sets were pulmonary vein isolation (PVI), left-extended (PVI þ mitral valve annulus [MV]
lesion  left atrial appendage lesion [LAA]) or biatrial-extended (right atrial ablation þ PVI þ MV  LAA).
Results: The success rates of PVI, left-extended, and biatrial-extended lesions were as follows: at 3 months,
56.7%, 74.7%, and 79.4% (P ¼ .003); at 6 months, 56.9%, 72.9%, and 74.6% (P ¼ .02); at 9 months,
54.6%, 72.5%, and 83.3% (P< .001); and at 12 months, 52.6%, 76.1%, and 80.0% (P< .001). Biatrial
lesions had a higher rate of pacemaker placement than did left atrial lesions (16.5% vs 7.5%; P ¼ .02).
When we grouped patients by left lesion (PVI, PVI þ MV, PVI þ MV þ LAA) irrespective of
right atrial ablation, success was as follows: 3 months, 57.9%, 71.1%, and 87.8% (P< .01); 6 months,
58.1%, 71.6%, and 77.6% (P ¼ .03); 9 months, 55.9%, 71.3%, and 89.6% (P< .01); and 12 months,
54.1%, 74.7%, and 83.7% (P< .01).
Conclusions: PVI is associated with lower rhythm success than an extended left atrial lesion set. The addition of
a right atrial lesion to an extended left atrial lesion set does not improve efficacy, but it does increase the rate of
pacemaker placement for sinus dysfunction. Adding an LAA lesion may confer additional efficacy when added
to a lesion set that includes PVI þ MV. (J Thorac Cardiovasc Surg 2013;145:356-63)Atrial fibrillation (AF), the most common arrhythmia, is
prevalent in 5.9% of persons older than 65 years.1 The ab-
solute number of persons with AF will continue to rise as
our population ages. In addition to the discomforting symp-
toms of palpitations, shortness of breath, anxiety, and re-
duced exercise tolerance, AF gives rise to hemodynamic
and physiologic changes resulting in tachycardia-induced
cardiomyopathy or thrombus formation and subsequent
stroke. AF is an independent predictor of mortality.2 Fur-
thermore, the economic burden of AF treatment in the
United States is significant with an annual cost of $6.65
billion.3
A variety of surgical approaches to AF treatment have
been introduced. In an effort to decrease procedureivision of Cardiothoracic Surgery, Department of Surgery, Columbia Univer-
ew York, NY.
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The Journal of Thoracic and Cardiovascular Surgcomplexity, time, and risk,4 the cut-and-sew Cox maze III
procedure has been replaced with modified procedures
that use ablative energy sources. Some have called this var-
iation the Cox maze IV procedure. Although the Cox maze
IV procedure replicates the full biatrial lesion pattern of the
cut-and-sewmaze,5 a variety of less extensive variations, in-
cluding procedures that include only left atrial lesions, are
frequently performed.
Despite the popularity of ablative procedures limited
only to the left atrium, some have suggested that left atrial
lesion sets are inadequate and inferior to more complete,
biatrial approaches.6-10 For this reason, we sought to
analyze our experience with a variety of approaches for
biatrial versus left atrial AF ablation.
METHODS
From January 2007 to November 2011, 305 consecutive patients under-
went surgical ablation for AF at 1 institution. In the majority of cases, the
procedure was performed in conjunction with other cardiac procedures.
Concomitant procedures included mitral valve surgery (33.3%,
n ¼ 100), aortic valve surgery (15.1%, n ¼ 46), coronary artery bypass
graft (3.9%, n ¼ 12), bypass grafting plus valve (18.0%, n ¼ 55), 2 or
more valves (17.7%, n ¼ 54), stand-alone ablation surgery (4.6%,
n ¼ 14), and other (7.8%, n ¼ 24). Baseline demographics are detailed
in Table 1.
Surgical ablation was performed biatrially or on the left atrium only.
The decision to perform biatrial versus left atrial ablation was determinedery c February 2013
Abbreviations and Acronyms
AF ¼ atrial fibrillation
BeLA ¼ biatrial with extended left atrial lesions
eLA ¼ extended left atrial lesions
LAA ¼ left atrial appendage
MV ¼ mitral valve annulus
PVI ¼ pulmonary vein isolation
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dardized to include 3 lesions to the tricuspid valve annulus, right atrial free
wall, and intercaval line (Figure 1). Left atrial ablation procedures were
categorized as either pulmonary vein isolation only (PVI) or ‘‘extended
left atrial lesion set,’’ consisting of PVI isolation plus a lesion to the mitral
valve annulus (MV), with or without a lesion to the left atrial appendage
(LAA).
Ninety-one patients received a biatrial lesion set, and 214 patients un-
derwent left atrial ablation only. Energy modality for ablation consisted
of cryoablation (n ¼ 145), radiofrequency (n ¼ 94), microwave
(n ¼ 65), and laser (n ¼ 1). Operative characteristics are detailed in
Table 1. Our primary end point was rhythm success defined as freedom
fromAF or atrial flutter. This was determined by 12-lead electrocardiogram
at 3, 6, 9, and 12 months after surgical ablation. Follow-up was 87%, 87%,
85%, and 84% at these time points, respectively. Missing data points at
various time points were left blank and not counted as procedure success
or failure. There was no difference among groups as divided by lesion
set with regard to completeness of follow-up. Freedom from antiarrhyth-
mics was not incorporated in the primary end point. Secondary end points
included mortality and hospital length of stay, as well as postoperative
myocardial infarction, stroke, and pacemaker placement. This study was
approved by our institutional review board and used informed consent.
The LAAwas managed in a few ways. If the base of the appendage was
noted to be broad, it was left open. Otherwise, the appendagewas oversewn
with a 2-layer closure. Alternatively, it was amputated with a stapler or ex-
cised and oversewn.
Statistical Analysis
Outcomes were compared using c2 or Fisher’s exact tests for categorical
variables and the Student t test for continuous variables expressed as
mean standard deviation. Differences in baseline demographics or oper-
ative characteristics were accounted for by stepwise backward logistic re-
gression. Univariate variables with a significance of P<.10 were entered in
a backward stepwise logistic regression. Stata version 11 (Stat Corporation,
College Station, Tex) was used for statistical analysis.RESULTS
Patient Characteristics
Our surgical cohort consisted of 305 patients, of whom
29.8% (n ¼ 91) had biatrial ablation and 70.2%
(n ¼ 214) had left atrial ablation. Baseline characteristics
were similar between groups, except the left-sided ablation
cohort tended to be older (68  12 vs 59 28; P<.01) and
more frequently white (78.0% vs 64.8%; P ¼ .02) and hy-
pertensive (73.8% vs 55.0%; P<.01), and patients in the
biatrial group had a higher incidence of prior cardiac sur-
gery (23.1% vs 13.1%; P ¼ .03). With regard to operative
characteristics, biatrial ablation was more frequently per-
formed via sternotomy as opposed to a minimally invasiveThe Journal of Thoracic and Caapproach (87.6% vs 76.9%; P¼ .03) and with an equal dis-
tribution of energy modalities, including cryoablation
(33.6%), radiofrequency (36.9%) and microwave (29%).
The biatrial ablation group had longer cardiopulmonary by-
pass times (152 34minutes vs 136 54minutes; P¼ .03)
and crossclamp times (98 41 minutes vs 86 41 minutes;
P ¼ .02). Patients whose concomitant procedure was
mitral valve surgery were more likely to have left atrial
lesions (38% vs 21%; P<.01).
Biatrial Versus Left Atrial Lesions Sets
First, we compared patients having biatrial lesions with
those having left atrial ablations. Rhythm success was supe-
rior in the biatrial cohort at all time points (80.3% vs 64.0%
at 3 months, P¼ .01; 75.7% vs 63.4% at 6 months, P¼ .06;
84.1% vs 61.9% at 9 months, P<.01; and 80.9% vs 62.4%
at 12 months, P<.01).
Because a range of left atrial lesion sets was used in our
patient cohort, from isolated PVI to more extensive left
atrial lesion patterns, we sought to determine the contribu-
tion of this variability to rhythm success. In our biatrial
cohort, 95% (n ¼ 86) had extended left-sided lesions as
compared with 40% (n ¼ 86) in the left-sided ablation
group. In the biatrial group, 40 patients had 3 lesions
(PVI þ MV þ LAA), 46 patients had 2 lesions
(PVI þ MV), and 5 patients had only PVI. In the left-
sided ablation group, 22 patients had 3 lesions, 64 patients
had 2 lesions, and 128 patients had only PVI (Figure 2).
Next, the cohort was divided into 3 groups: PVI only
(PVI), extended left atrial lesions (eLA), and biatrial with
extended left atrial lesions (BeLA). The success rates of
PVI, eLA, and BeLA lesions were as follows: 3 months,
56.7%, 74.7%, and 79.4% (P ¼ .003); 6 months, 56.9%,
72.9%, and 74.6% (P ¼ .02); 9 months, 54.6%, 72.5%,
and 83.3% (P< .001); and 12 months, 52.6%, 76.1%,
and 80.0% (P<.001). Through 12months, PVI was inferior
to eLA or BeLA lesions. However, there was no difference
in success over this time period between patients receiving
biatrial or left-sided cohorts when the left lesions were more
complete (eLA) (Figure 3).
To account for differences among group characteristics,
we performed a stepwise backward multivariable logistic
regression. This model took into account differences in
demographic characteristics including age, race, history
of hypertension, and previous cardiac surgery as well as
differences in operative characteristics including differ-
ences in energy modality, cardiopulmonary bypass time,
and crossclamp time. As compared with a biatrial ex-
tended lesion set, PVI had inferior rhythm success at 3
months (odds ratio [OR], 0.34; confidence interval
[CI], 0.17-0.69; P ¼ .003), 6 months (OR, 0.45; CI,
0.23-0.88; P ¼ .02), 9 months (OR, 0.24; CI, 0.11-0.51;
P ¼ .001), and 12 months (OR, 0.28; CI, 0.13-0.58;
P ¼ .001). In our multivariable analysis, there was nordiovascular Surgery c Volume 145, Number 2 357
FIGURE 2. Distribution of left lesions in biatrial and left atrial lesion
groups. PVI, Pulmonary vein isolation; MV, mitral valve annulus;
LAA, left atrial appendage.
TABLE 1. Preoperative and operative characteristics
Preoperative characteristics
Biatrial
(% of patients)
Left atrial
(% of patients)
P
value
No. 91 214 —
Age (y) 59  28 68  12 <.01
Female gender 40.7 45.8 .41
White race 64.8 78 .02
Body mass index 28  6 27  6 .6
Current smoker 3.3 7.5 .17
Diabetes 17.6 18.7 .82
Hypertension 55 73.8 <.01
Hyperlipidemia 27.5 35.6 .23
Stroke 9.9 8.9 .78
Coronary artery disease 30.8 42.1 .06
Congestive heart failure 41.8 34.6 .23
Previous cardiac surgery 23.1 13.1 .03
Depression 5.5 5.1 .89
Left atrial size (cm) 4.9  0.8 5.1  0.9 .14
AF chronicity: paroxysmal 33.7 31.8 .75
Operative characteristics
Sternotomy approach 87.6 76.9 .03
Radiofrequency 16.5 36.9 <.01
Cryoablation 80.2 33.6 <.01
Microwave 3.3 29 <.01
Laser 0 0.47 .51
Crossclamp time (min) 98  41 86  41 .02
CPB time (min) 152  34 136  54 .03
AF, Atrial fibrillation; CPB, cardiopulmonary bypass.
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rhythm success.Concomitant Mitral Surgery Subset
To minimize the confounding influence of concomitant
procedure heterogeneity, we repeated the analysis in the
subset of our patients who had concomitant mitral valve sur-
gery (n ¼ 100). In our mitral valve cohort, 19 patients had
BeLA, 44 had eLA, and 37 had PVI. There were noFIGURE 1. Right atrial lesion set (courtesy of Marc Gillinov, MD).
358 The Journal of Thoracic and Cardiovascular Surgdifferences in baseline characteristics for this subset of pa-
tients. With respect to operative characteristics, the only
significant difference was the more frequent use of cryoa-
blation as in the BeLA group versus the eLA group
(84.2% vs 45.0%; P< .01). Rhythm success in the PVI,
eLA, and BeLA groups was as follows: at 3 months,
62.1%, 79.5%, and 93.8% (P ¼ .05); at 6 months, 65.5%,
82.1%, and 87.5% (P ¼ .15); at 9 months, 65.5%, 84.2%,
and 93.3% (P ¼ .06); and at 12 months, 62.1%, 86.5%,
and 86.7% (P ¼ .04). The univariate analysis demonstrated
the inferiority of PVI and no difference between eLA and
BeLA lesion sets andwas confirmed onmultivariable logistic
regression that took into account differences in energy
modality.Extent of Left Atrial Lesion Set
Next, we sought to investigate further the impact of the
extent of the left atrial ablation on rhythm success. That
is, did performing 3 left lesions confer greater efficacy
than 2 left lesions, irrespective of whether right-sided abla-
tion was performed? To that end, we grouped patients by
left lesion set irrespective of right atrial ablation. Rhythm
success for PVI, 2 left lesions, and 3 left lesions was as
follows: 3 months, 57.9%, 71.1%, and 87.8% (P ¼ .001);
6 months, 58.1%, 71.6%, and 77.6% (P ¼ .03); 9 months,
55.9%, 71.3%, and 89.6% (P< .001); and 12 months,
54.1%, 74.7%, and 83.7% (P<.001) (Figure 4). Multivari-
able analysis to account for differences in baselineFIGURE 3. Rhythm success with pulmonary vein isolation (PVI), ex-
tended left atrial lesions (eLA), and biatrial with extended left atrial lesions
(BeLA).
ery c February 2013
FIGURE 4. Rhythm success stratified by completeness of left atrial le-
sion. PVI, Pulmonary vein isolation; MV, mitral valve annulus; LAA, left
atrial appendage.
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inferiority of PVI as compared with 3 left lesions—rhythm
success for PVI as compared with the 3 left lesion group
was as follows: OR, 0.19; CI, 0.08-0.49 at 3 months
(P ¼ .001); OR, 0.40; CI 0.18-0.87 at 6 months
(P ¼ .02); OR, 0.15; CI, 0.05-0.40 at 9 months
(P < .001); and OR, 0.23; CI, 0.10-0.54 at 12 months
(P ¼ .002). Multivariable analysis also suggested that 2
left lesions were inferior to 3 left lesions, at least at the 3-
month (OR, 0.34; CI, 0.13-0.90; P ¼ .03) and 9-month
(OR, 0.29; CI, 0.10-0.81; P ¼ .02) time points.
Again, we repeated this analysis in our mitral valve sub-
set. The success of PVI, 2 left lesions, and 3 left lesions, re-
gardless of right atrial ablation, was 62.1%, 79.0%, and
94.1% at 3 months (P ¼ .04), 65.5%, 79.0%, and 94.1%
at 6 months (P ¼ .08), 65.5%, 81.1%, and 100% at 9
months (P ¼ .02), and 62.1%, 83.3%, and 93.8% at 12
months (P ¼ .03). On multivariable logistic regression,
PVI was inferior to 3 left lesions at 3 months (OR, 0.10;
CI, 0.01-0.88; P ¼ .04), 6 months (OR, 0.12; CI,
0.01-1.0; P ¼ .05), and 12 months (OR, 0.08, CI,
0.01-0.9; P ¼ .04), whereas there was no difference in effi-
cacy between 2 left lesions versus 3 left lesions at 3 months
(OR, 0.23; CI, 0.03-2.0; P ¼ .19), 6 months (OR, 0.23; CI,
0.03-2.0; P ¼ .19), and 12 months (OR, 0.35; CI, 0.04-3.4;
P ¼ .36).
Morbidity
With respect to our secondary outcomes, patients having
biatrial ablation lesions had a higher rate of pacemaker
placement than did those having only left atrial lesions
(16.5% vs 7.5%; P ¼ .02). We further investigated theTABLE 2. Indications for Pacemaker Placement
Indications eLA BeLA MV cohort eLA MV cohort BeLA
AV bock 3.7% 4.4% 3.7% 5.3%
Sinus Dysfunction 3.7% 12.1% 4.9% 21.1%
eLA, Extended left atrial lesions; BeLA, biatrial with extended left atrial lesions;
MV, mitral valve annulus; AV, atrioventricular.
The Journal of Thoracic and Careason for pacemaker placement to clarify whether the
pacemaker placement was related to the concomitant proce-
dure or the ablation (Table 2). Performing a 2-valve proce-
dure at the same time as surgical ablation was a risk factor
for pacemaker placement. However, there was no difference
in the frequency or the type of double valve procedures be-
tween the groups to account for the different rates of pace-
maker placement. In addition, other operative parameters
including bypass time, energy modality, and surgeon were
not predictors of postoperative pacemaker placement. In
the overall patient cohort, although there was no difference
in the incidence of atrioventricular block as the indication
for pacemaker insertion between the biatrial versus left
atrial ablation groups (4.4% vs 3.7%; P ¼ .79), the inci-
dence of sinus bradycardia or arrest was significantly higher
in the biatrial group (12.1% vs 3.7%; P<.01). In the mitral
valve subset, there was also a higher rate of pacemaker
placement in the biatrial cohort as compared with the left
atrial ablation cohort (26.3% vs 8.6%; P ¼ .03). Again,
there was no difference in the frequency of atrioventricular
block as the indication for pacemaker placement in the bia-
trial versus the left atrial ablation groups (5.3% vs 3.7%;
P¼ .76), but there was a much higher rate of sinus dysfunc-
tion in the biatrial group (21.1% vs 4.9%; P ¼ .02).
There was no difference between biatrial or left-sided ab-
lation groups with respect to hospital length of stay
(11.2  10.9 vs 10.5  9.1; P ¼ .58) or 30-day mortality
(3.8% vs 3.2%; P ¼ .80). There was no difference with re-
gard to major postoperative complications including myo-
cardial infarction (0% vs 0.5%; P ¼ 1.0) and stroke
(3.8% vs 3.7%; P ¼ .97).
DISCUSSION
In our initial analysis of our 305-patient cohort, we found
a higher success rate through 12 months in those receiving
biatrial versus left atrial lesion sets. This finding was consis-
tent with those of other studies that have concluded that bia-
trial ablation is superior to left-sided lesions. However,
these studies grouped all left lesions together8,11 and
incorporated energy modalities no longer in use. When
the left lesion set has been deconstructed, there have been
a myriad of left lesion sets that have been compared with
biatrial lesion sets. These lesion sets have included
ganglionic plexi ablation,6 coronary sinus lesions,7 as well
as cavotricuspid isthmus lesions.10 The results have been
conflicting with reports of superior efficacy in the biatrial
group6,7 versus no difference in efficacy.9,12,13 It is
difficult to compare studies given the heterogeneity of
lesions performed.
Further analysis of our detailed lesion set data revealed
that the overwhelming majority of the patients in our
biatrial cohort had extended left lesions sets
(PVI þ MV  LAA), whereas the majority of those in
the left-sided cohort had only PVI. Thus, we expandedrdiovascular Surgery c Volume 145, Number 2 359
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observed in the biatrial cohort was attributable to the addi-
tion of a right-sided lesion, or rather to the more frequent
presence of an extended left lesion set. When we broke pa-
tients down by extensiveness of the left atrial lesion, we
found that the efficacy of eLA lesion set and the biatrial le-
sion set (BeLA) were similar and that both were superior to
PVI alone. This finding conflicts with reports of satisfactory
outcomes with PVI14-16 and corroborates another study that
linked PVI alone to inferior outcomes.17 This may be re-
lated to the high proportion of persistent AF in our PVI
cohort.
Although there were no differences in the groups with re-
spect to important known predictors of ablation efficacy,
such as left atrial size and chronicity of AF, we performed
a multivariable analysis to account for other demographic
and technical differences. Even after accounting for these
potential confounding factors in our multivariable analysis,
we found that there was no difference in success rate be-
tween an extended left atrial lesion set (eLA) and a biatrial
lesion set (BeLA). These findings were also confirmed in
the more homogeneous group of patients having mitral sur-
gery as their concomitant procedure. Thus, in our patient
cohort, it appears that the superior efficacy of biatrial abla-
tion over left atrial ablation was a result of the fact that an
extended left atrial lesion set (which is superior to PVI
alone) was more commonly used in the biatrial procedures.
In addition, we found that 3 left lesions may confer an ad-
ditional efficacy benefit as compared with 2 left lesions.
Other studies have noted the MV lesion as an important ad-
dition to PVI.17,18 In some cases, the LAA is an important
trigger of AF.19 Our data suggests that the LAA lesion
may be an important component of the left atrial lesion
set in addition to the MV lesion.
We wanted to investigate the risk factors associated with
postoperative pacemaker placement. We found that per-
forming 2 valve procedures at the same time as surgical ab-
lation was a predictor of postoperative pacemaker
placement. However, there was no difference in either the
frequency or type of double valve procedures in the biatrial
versus the left atrial ablation cohorts. To further adjust for
possible confounders, we examined pacemaker placement
in our mitral valve cohort and it confirmed our finding of
biatrial ablation as a predictor of postprocedure sinoatrial
node dysfunction. Other operative characteristics including
bypass time, energy modality, and surgeon were not predic-
tors of postoperative pacemaker placement.
The reported rates of pacemaker placement in the litera-
ture range from 5% to 10%,14,20,21 but few studies have
reported the rate of pacemaker placement after right atrial
lesions.7,22 We observed a higher rate of pacemaker
placement in our biatrial cohort. There were no
differences between the left-sided cohort and the biatrial co-
hort with respect to postprocedure atrioventricular block,360 The Journal of Thoracic and Cardiovascular Surgand the increased pacemaker requirement in the biatrial
group was related an increased incidence of sinus dysfunc-
tion. These findings were confirmed in the concomitant mi-
tral surgery subset as well. We23 have previously published
our findings noting that postoperative pacemaker placement
after surgical ablation was an independent predictor of
short-term mortality. Thus, this complication is not neces-
sarily without consequence.
As this experience encompasses several years and as en-
ergy modalities in favor have changed over the years, there
is a certain heterogeneity to our experience. We tried to ac-
count for these differences in energy modality in a number
of ways. First, we limited our experience to the past 5 years
to encompass more contemporary energy modalities and,
indeed, radiofrequency and cryoablation constituted the
majority of our experience. Second, we accounted for dif-
ferences in energy modality in our multivariable model.
Third, we performed a subanalysis on our more homoge-
nous MV cohort.
There has been the suggestion that procedure success is
dependent on the operator. We investigated this question
in our experience. Surgical ablation has been performed at
Columbia since the late 1990s, and our AF database has
maintained records since 1999. The operators who consti-
tuted the majority of procedures performed (91.5%) had
the same level of experience. Operator was not a predictor
of procedure success.
Our study has several limitations. First, although demo-
graphic and operative data were collected prospectively in
our clinical research database, all analyses were performed
retrospectively. Consequently, our findings support an asso-
ciation between events rather than a definitive cause and ef-
fect relationship. Also, the specific procedures performed in
our patients were not based on randomized assignment or
even specific predetermined criteria, but rather on clinical
practice norms and surgeon preference. Although we at-
tempted to take known differences in patient characteristics
and operative details into account by applying multivariable
statistical techniques, our study remains vulnerable to the
pitfalls of a nonrandomized, retrospective analysis, includ-
ing unknown confounders and selection, procedure, and de-
tection bias. Second, we determined rhythm success by
quarterly 12-lead electrocardiographic analysis. Although
this method allowed for excellent follow-up rates and repre-
sented the only practical way of getting this degree of data
completeness given the demographic and geographic pro-
file of our patients, it is subject to the risk of underdetection
of arrhythmias and therefore overestimation of success
rates. Third, our follow-up was only short term, although
we are actively collecting long-term data. Fourth, although
this study represents a large single-center cohort, the divi-
sion of patients into subgroups limited our study power. Fi-
nally, our cohort includes a heterogeneous population with
respect to concomitant procedures. This lends itself toery c February 2013
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arrhythmia pathophysiology. A subanalysis of the mitral
valve cohort attempted to correct for this, but the reduced
study numbers further decreased the statistical power of
this analysis.
In summary, we found that PVI is associated with lower
efficacy than more extensive left atrial lesion sets and that
the addition of right atrial lesions to an extended left atrial
lesion set does not improve efficacy, but increases the rate of
pacemaker implantation for sinus dysfunction. Given the
limitations outlined above, our results are certainly not de-
finitive. However, inasmuch as our study does describe
a substantial real-world experience with a variety of lesion
sets in a representative cardiac surgical population with AF,
we believe that our findings are worth pursuing in a more
rigorous way. We eagerly await the results of an ongoing
National Institutes of Health trial studying the efficacy of
left atrial and biatrial lesion sets in patients with AF who
are undergoing mitral valve surgery.References
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Dr Ralph J. Damiano (St Louis, Mo). Dr Soni, I congratulate
you on a beautiful presentation and for both rigorously looking
at your data and acknowledging the limitations of this study. I
also thank you for providing me with your slides before your talk.
In this work, DrArgenziano and colleagues have presented a ret-
rospective review of 305 patients undergoing primarily concomi-
tant surgical AF ablation. They examined the impact of the
lesion set performed on outcomes at 3, 6, and 12 months. The prin-
cipal conclusion of this study was that the efficacy of their biatrial
lesion set (BeLA) was similar to that of an extended left atrial le-
sion set (eLA), albeit the incidence of pacemaker implantation was
higher in patients who had right atrial lesions. I think this is an in-
teresting finding and certainly suggests the need for further study.
However, it is very difficult to interpret your data and almost im-
possible to draw any definitive conclusions.
The principal problem is that your 2 groups, patients with bia-
trial lesion sets and patients who just had various different left
atrial lesion patterns alone, were very different in terms of their de-
mographics, their operative characteristics, and the ablation tech-
nology that was used to create the lesions. Moreover, the 2 groups
had, as you showed in one of your slides, significantly different left
atrial lesion patterns. In the biatrial group (BeLA), only 5% of pa-
tients had PVI alone on the left side, whereas 60% of the patients in
the left-sided alone group had just PVI as their left atrial lesion set.
I would suggest that the marked differences between these 2
groups suggests there was fairly significant uncontrolled selection
biases in how you decided what to do and patient and procedural
differences that likely have influenced your results.
My first question for you is whether you performed any case-
matched comparison or tried to do a propensity analysis to control
for these marked differences between the 2 groups.rdiovascular Surgery c Volume 145, Number 2 361
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study, we attempted to do a propensity analysis to account for dif-
ferences among groups, which is themain limitation of a retrospec-
tive study. However, owing to the limited number of patients in the
subgroupings of lesion sets, we were unable to perform a propen-
sity analysis. In lieu of this, we adjusted for differences in patient
populations using a stepwise backward multivariate logistic re-
gression. To further adjust for confounders, we did a subanalysis
of biatrial versus left lesion sets in patients who had concomitant
valve surgery. In this cohort, there were no differences in baseline
characteristics among the groups. Our analysis in our mitral valve
cohort corroborated our findings that we presented in our larger co-
hort. As we expand our patient cohort over time and increase our
study power, we will revisit this finding with respect to the general
cohort as well as the various subgroups.
Dr Damiano. I agree. As you accumulate more patients in your
series, it would be interesting to do a more detailed analysis.
The other problem, and you acknowledge this, is that the fol-
low-up in reporting of your results does not follow the recommen-
dations of both the 2007 and 2012 expert consensus statements on
surgical and catheter ablation. Success has to be defined as free-
dom from both AF and atrial flutter, and I would add atrial tachy-
cardia at 12 months. And freedom from arrhythmia has to be off
antiarrhythmic drugs. Not controlling for the use of antiarrhythmic
drugs, particularly in this population, would completely confuse
your results. Many of these patients came in never having been
on antiarrhythmic drugs because they were primarily being re-
ferred for correction of valvular or coronary disease.
If you used the correct end point, which would be freedom from
both atrial tachyarrhythmias and antiarrhythmic drugs at 12
months, would you still have had the same results?
Dr Soni. With respect to antiarrhythmic drugs, that is some-
thing that we are currently evaluating. In the absence of continuous
rhythm monitoring, by using spot electrocardiograms, we are go-
ing to overestimate our success. Furthermore, presenting outcomes
with respect to rhythm instead of rhythm and freedom from antiar-
rhythmic drugs will also tend to overestimate success. However,
inasmuch as the incidence of paroxysmal AF is the same in the var-
ious groups, I would not expect that we overestimated rhythm suc-
cess in 1 group as compared with another. Thus, although this topic
will need to be revisited, we would expect our findings to be
representative.
Dr Damiano.We have found that with relatively low incidence
of recurrence of AF, if you use a stricter end point, which is requir-
ing patients to be off antiarrhythmic drugs, it is much easier to dis-
cern differences between groups.
I would ask my next quick question for you. You obviously had
some patients who had prolonged monitoring. The consensus
statement defined that the minimum acceptable follow-up is
24-hour Holter monitoring. Can you separate the patients who
had at least 24-hour Holter monitoring and reanalyze your data?
Would this change your results?
Dr Soni. That is something that we are taking a look at right
now to further investigate the differences between the patients
who had continuous rhythm monitoring versus those who did not.
Dr Damiano. My final quick question is that pacemaker im-
plantation is a rough and inexact end point in that it depends on
why they had the pacemaker implanted, especially when 96% of362 The Journal of Thoracic and Cardiovascular Surgthe patients had concomitant surgical procedures. Complete heart
block is a complication of valve surgery; it is not a complication of
a maze procedure. There is no way to get complete heart block un-
less you do a lesion set across the atrioventricular node, which is
not described, as far as I know, in any lesion set, nor was it used
in your right atrial lesion pattern.What was the indication for pace-
makers in your series? How many patients had a pacemaker for
complete heart block, which is a complication of the concomitant
surgery, versus how many had a pacemaker put in for sinus node
dysfunction, which is either a complication of the AF or
potentially of the right atrial lesion set?
Dr Soni. The majority of patients had the pacemaker placed for
sinus node dysfunction. This was true in our general cohort as well
as the subanalysis in our mitral valve cohort. There was no differ-
ence in atrioventricular node dysfunction between biatrial or left-
sided lesion set groups. This would indicate that pacemaker
placement was not related to the concomitant procedure but rather
the surgical ablation itself.
Dr Damiano. My point is that it is hard to blame that on the
right atrial lesion set inasmuch as it cannot result in atrioventricu-
lar nodal dysfunction. It can theoretically cause sinus node dys-
function. It may be interesting to look at your data a little more
carefully with this in mind.
Dr Vinay Badhwar (Pittsburgh, Pa). We, like others, support
your interest in homogeneity in reporting, and so I congratulate
you for that.
As you know, tricuspid annular dimension may affect the deci-
sion to perform a tricuspid valve repair concomitantly at the time
of a maze procedure. Have you looked at the tricuspid annular di-
mension in your cohort of patients who had biatrial lesion sets as
well as those with left atrial only lesion sets? How many of those
patients had a tricuspid valve repair and was this a factor in
prompting the biatrial lesion set? If not, have you looked at late in-
cidence of return of tricuspid regurgitation in your patient cohort in
both groups and has this changed how you approach patients now,
particularly in those with a tricuspid annular dimension approach-
ing or greater than 4 cm?
Dr Soni. The concomitant procedure played a role in determin-
ing the extent of the ablation. That is, when there was a reason to
open the right atrium or, for that matter, the left atrium, a more lim-
ited lesion set was often performed. You raise a very interesting
question with regard to the tricuspid valve. Patients who received
concomitant tricuspid valve surgery actually represented a very
small proportion of patients in our cohort. Furthermore, our data-
base is a retrospective database. Although some of our data were
collected prospectively with regard to operative data, we do not
have data regarding the preoperative tricuspid valve annular di-
mension, so we have not taken a look at that. Moving forward, it
would interesting evaluate that in the future.
Dr Takashi Nitta (Tokyo, Japan). I have 1 comment and a ques-
tion. We did an intraoperative mapping study in the patients with
AF to examine how the right atrium plays a role in sustenance
of AF. The results were presented in this meeting and the paper
was published in this Journal in 2005.
Most of the patients with paroxysmal AF showed a focal ac-
tivation arising from the pulmonary vein and the right atrium, in-
dicating the left atrium only lesion set would be enough to
terminate AF. However, three quarters of the patients withery c February 2013
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dicating the biatrial lesion set would be necessary to eliminate
AF. From our data, I believe that the patients who underwent
the left atrium only lesion set still have the substrate for AF in
the right atrium and should be carefully followed up for the
recurrence of AF.
In our mapping study, most of the patients who showed a right
atrial reentry had a dilated right atrium, only the dilated left atrium.
Did you examine the effect of the size of the right atrium on the
results of the left atrium only lesion set?
Dr Soni. Would you please clarify your question?
Dr Nitta. To develop the right atrial reentry, the size of the right
atrium is more important than the left atrial size. Did you measure
the size of the right atrium?
Dr Soni.Again, that is not something that we had measured and
recorded in our database. However, we are currently taking a look
at echocardiographic characteristics in both of our groups and see
how that might have affected our outcomes.
DrEzzeldinMostafa (Cairo, Egypt). I actually have a comment
that is similar to that of my previous colleague about the morphol-
ogy. I guess you have to add to the title, ‘‘in nonrheumatic pa-
tients,’’ because rheumatic patients have a giant right atrium and
a giant left atrium and sometimes rheumatic carditis to the right
atrium, actually necessitating the right atrial maze. That is why
we should add ‘‘in nonrheumatic patients.’’
My question concerns the protocol you are using. Does the pro-
tocol contain amiodarone in intraoperative and postoperative man-
agement to maintain the sinus rhythm, or do you not add
amiodarone?The Journal of Thoracic and CaDr Soni. Just to make sure I understand, you are asking about
the antiarrhythmic regimen after surgery?
Dr Mostafa. Intraoperatively and postoperatively.
Dr Soni.We found that postoperative arrhythmia is not predic-
tive of long-term rhythm success in our cohort. Postoperatively, we
treat our patients with a class 1, 2, or 3 antiarrhythmic for 6 weeks.
At our 6-week return visit, if they are in sinus rhythm at that point,
we stop antiarrhythmic therapy. If they are not in sinus rhythm, the
termination of their antiarrhythmic therapy is left up to the discre-
tion of their cardiologist. Intraoperatively, we do not use
amiodarone.
Dr Mostafa. What about the nonrheumatic pathology? In the
rheumatic pathology, I do not find that an isolated left atrial lesion
is complete for the revision. I guess a biatrial maze should be
added.
Dr Soni. With regard to rheumatic pathology, that represents
a very small percentage of patients in our cohort. We would not
be able to look at that with any sort of definitive answer. When
we repeated the analysis in our mitral valve cohort, we found the
same results in our larger cohort.
Dr Mostafa. Thank you.
Dr Craig R. Smith (New York, NY). I have 1 quick question for
my colleagues. In your conclusions you mention completeness as
having some influence on the outcome. Remind us how you
defined or measured completeness.
Dr Soni. The completeness was with regard to the extent of the
left lesion set. A more extensive lesion set as defined by the addi-
tion of a mitral valve annulus lesion to PVI with or without an LAA
lesion is predictive of success.rdiovascular Surgery c Volume 145, Number 2 363
